Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Ownership and Inventorship Ambiguity Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those…
A Five-Part Series on AI Drug Discovery Valuation Challenges Introduction I have no idea. That was my brilliant, insightful, memorable, put this on a t-shirt answer to the question posed…
Introduction Part I of this article proposed a framework to help guide the discussion around repurposing, which we define very broadly. Now, in Part II, we extend the framework and…
Introduction Repurposing was at one time a very popular strategy, with some of the earliest blockbusters being novel formulations (usually new oral sustained release versions) of existing products. Generous regulatory pathways (like…
Finding myself with a lengthy layover at the Dublin Airport in Swords, Ireland, on my way to New York from BIO-Europe (and with a surprising lack of Guinness at the…
The US FDA recently published an interesting discussion paper, entitled Using Artificial Intelligence & Machine Learning in the Development of Drug and Biological Products. Here is a link to the…
It seems as if nobody talks about anything except AI these days, especially in the drug discovery part of our industry. And why not? In a relatively short period of…